Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the best mid-cap growth stocks to buy right now. On January 13, Baird analyst Brian Skorney raised the firm’s price target on Mirum Pharmaceuticals to $95 from $81, while maintaining an Outperform rating. This revision came as the firm updated its valuation model after preliminary results delivered a beat-and-raise on earnings and guidance. The stronger-than-expected data provides a solid foundation heading into a high-activity year in 2026. Furthermore, ...